Innovative Biochips, LLC Awarded Phase II Grant Support from the National Institutes of Health
Innovative Biochips, LLC has been awarded a National Institutes of Health (NIH) Small Business Technology Transfer (STTR) Phase II grant. This Phase II grant ($1,500,000) supports to continue the research and development efforts of Innovative Biochips for developing an automated dissection system initiated in Phase I grant ($225,000). The Phase II funding is based on the results achieved in Phase I and the scientific and technical merit and commercial potential of the Phase II project proposed. Only Phase I awardees are eligible for a Phase II award.
Financial Conflicts of Interest Policy
This Policy implements Financial Conflicts of Interest (FCOI) disclosure requirements found in 42 CFR Part 50 and 45 CFR Part 94 which are applicable to Research funded by the U.S. Public Health Service (PHS). As a condition for receiving PHS funding, these regulations require Innovative Biochips LLC to maintain an appropriate written policy on financial conflict of interest disclosure, and make such policy available via a publicly accessible Web site. The Innovative Biochips' FCOI Policy and FCOI Disclosure Form can be found below.
Fierce Innovation Awards: Life Sciences Edition Announce Finalists, Innovative Biochips Recognized
Innovative Biochips has been selected as a finalist in this year’s Fierce Innovation Awards: Life Sciences Edition, an awards program from the publisher of FierceBiotech and FiercePharma. Innovative Biochips was recognized as a finalist in the category of Biotech Innovation.
ADDRESS: 202 Industrial Blvd, Suite 703, Sugar Land, TX 77478, USA